SCG Cell Therapy And A*STAR Launch Joint Labs To Advance iPSC Technology For Scalable GMP Manufacturing Of Cellular Immunotherapies
Collaboration aims to develop scalable GMP-grade iPSC manufacturing processes and therapeutic candidates to facilitate research leading to translation of novel cellular immunotherapies.
Launch of the joint labs builds on existing license, research collaboration and Memorandum of Understanding between SCG Cell Therapy and A*STAR.
Panasonic and Shinobi Therapeutics Partner to Develop Efficient and Cost-Effective iPS Cell Therapy Manufacturing Technology
Panasonic to create a closed-system manufacturing device based on Shinobi’s innovative iPS-T cell platform and cutting-edge research at Kyoto University
Partnership aimed at significantly broadening accessibility of cell therapies to patients on a global scale
SAN FRANCISCO and KYOTO, Japan, April 18, 2024 — Shinobi Therapeutics, a biotechnology company developing a new class of immune evasive iPS cell therapies, today announced a partnership with Panasonic Holdings Corp and Kyoto University’s Center for iPS Cell Research and Application (CiRA). Through this strategic collaboration, the organizations aim to engineer a novel manufacturing platform to produce iPS-T cell therapies more efficiently and at lower cost than is possible with currently available technology. [Read more…]
What Are iPSCs, Who is Funding Them, and What Trials are Underway?
Induced pluripotent stem cells (iPS cells) can be made by reprogramming mature adult cells back into an embryonic-like state. Derived from skin or blood cells, iPS cells are not controversial, because they are made from adult cells. As pluripotent stem cells, they can give rise to all of the tissues that form the human body. [Read more…]
Kenai Therapeutics Emerges with $82M to Advance Its Allogeneic, iPSC-Derived Therapy for Parkinson’s Disease
Kenai Therapeutics has emerged from stealth mode with $82M to invest in its allogeneic iPSC-derived cell therapeutic for Parkinson’s disease (PD).
Proceeds to be used to complete clinical proof-of-concept trial for Kenai’s lead candidate, RNDP-001, for the treatment of Parkinson’s disease.
Financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group, with participation from Euclidean Capital and Saisei Ventures.
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 70
- Next Page »